BeiGene's PD-1/VEGF-A/CTLA-4 Trispecific Antibody Enters First-in-Human Trial; Merck Terminates Phase II Alzheimer’s Drug MK-1167

Jul 03, 2026 19:03 CST Updated 19:03

BeOne

Developer of Molecular Targeted and Immune Anti-Tumor Drugs

Huahui Health

Innovative Drug Developer

BeOne’s PD-1/VEGF-A/CTLA-4 Trispecific Antibody Initiates Clinical Trials for the First Time

Recently, the official website of the Drug Clinical Trial Registration and Information Publicity Platform showed that Huahui Health has registered a study to evaluateHH160Monotherapyan open-label, multicenter study of the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity in combination with other anticancer drugs,IPhase clinical trial.

Source: Official Website of the Drug Clinical Trial Registration and Information Publicity Platform

HH160is a targetedPD-1、CTLA-4andVEGF-Atriple-specific antibody.2026Year4month, BeOne and Huahui Health entered into a global exclusive option, license, and collaboration agreement for the product, with a total value of up to20.24100 million USD, with the down payment being2000in tens of thousands of US dollars, the exercise payment is1hundred million U.S. dollars. The launch of this initiative isHH160The First Clinical Study,Currently, only monotherapy studies are being conducted in China.。

The study is planned to enroll patients in China.45subjects enrolled internationally477subjects. The primary endpoint was treatment-emergent adverse events (TEAE), serious adverse events (SAE) and dose-limiting toxicities as defined in the protocol (DLT) incidence of events, andHH160maximum tolerated dose (MTD) or maximum administered dose (MAD). Secondary endpoints included objective response rate, disease control rate, duration of response, progression-free survival, and time to response, all based on investigator assessment.HH160ofPKParameters.

Deuterated Pirfenidone Biotech Secures $180 Million in Financing

7Month2Day,PureTechAnnounced, its incubated entitiesCelea Therapeutics(hereinafter referred to asCelea) The oversubscription amount reached1.8 private equity financing of $100 million;CeleaCore Pipeline Products Aredeupirfenidone（LYT-100), namely deuterated pirfenidone, is a drug used for idiopathic pulmonary fibrosis (IPF) and other candidate drugs for fibrotic lung diseases。

As disclosed, thisThe financing proceeds will be specifically allocated to four major segments:

Global Multicenter Pivotal RegistrationⅢPhaseSURPASS-IPFClinical trial initiation, subject enrollment, and full trial execution;

Long-Term Open-Label Extension for All Subjects (OLE) Safety follow-up study;

Pre-commercialization API and drug product manufacturing, preparation of regulatory submission dossiers, and global medical affairs layout, leveraging simplification505(b)(2)The regulatory submission pathway supports the simultaneous filing of marketing applications for this product in the United States and the European Union;

PromotiondeupirfenidonePipeline Expansion: Evaluating Therapeutic Potential in Fibrotic Indications Beyond Idiopathic Pulmonary Fibrosis

This time1.8Following the completion of the private placement worth hundreds of millions of US dollars,PureTech Health plcStill heldCelea TherapeuticsMajority equity; several leading cross-border healthcare investment institutions have become new institutional shareholders. The transaction agreement includes industry-standard anti-dilution provisions and tiered authorization fees based on clinical and commercialization milestones,PureTech Health plcPriority for Joint Promotion, All Rights ReserveddeupirfenidoneClinical development and commercialization performance-linked.

Merck & Co. Terminates Development of a Novel Alzheimer’s Disease Drug

7Month1Day, Merck & Co. inClinicalTrials.govofficially updated its portfolio of small-molecule Alzheimer’s disease candidate drugsMK-1167ofⅡPhase clinical trial (MK-1167-008) status, mark it as“Termination”。

MK-1167is a targetedα7Positive allosteric modulators of nicotinic acetylcholine receptors, originally developed to further improve cognitive and memory functions in patients with Alzheimer’s disease through combination therapy with standard acetylcholinesterase inhibitors (such as donepezil).

Merck & Co. stated that the core reason for termination was that the efficacy analysis failed to meet predefined criteria, insufficient to support continued R&D progression, while emphasizing that this discontinuation is unrelated to drug safety.

Layout: Yu Yuanze

Source: Official WeChat Accounts of Each Company